Global Genes is one of the world’s most prominent rare disease advocacy groups and early next year, they will host the second annual RARE in the SQUARE event.
At this highly anticipated event located in San Francisco’s Union Square, innovators, investors, and patients alike will have the opportunity to network in all things rare disease. Global Genes is partnering with J.P. Morgan’s Healthcare Conference to bring this event to fruition, which will give community leaders and rare disease influencers the opportunity to make important things happen and try to solve life-changing problems.
Rare disease stakeholders can do business at the apex of the J.P. Morgan conference, within a convenient location . This will all take place on January 8-10th, 2018.
Simultaneously, Global Genes has made another valuable partnership with EBD Group and Demy-Colton to present the 2018 Biotech Showcase called “Drivers of Innovation: Evolving Models in Rare Disease Drug Development.” This will be an exciting panel that will take an in depth look at the pharmaceutical business and the growing pressure on drug companies to develop new rare disease therapies in a cost-effective manner.
Danny Levine, the editor and host of RARECast will moderate the panel. The panel will also feature special guest appearances from VIP pharmaceutical leaders.
To learn more about the panel, click here.
If you’re an avid Patient Worthy reader, then you’ll know that we are advocates for rare diseases which affect 350 million people worldwide. The painful statistic is that 50% of rare disease sufferers are children, and 30% won’t live to see their fifth birthday.
Orphan drugs are being developed to combat these rare disease menaces, and they represent a large segment of the pharma industry’s drug development. The prices, however, keep getting more expensive. Analysts estimate that drug sales will grow 6.5% annually well into 2022.
“This is an important time for the rare community. Patient advocates are becoming active partners in progress, and helping to advance rare disease drug development like never before,” said Nicole Boice, CEO of Global Genes to Cision PR Newswire